Table 1.
Clinical data: ID, patient identification; M, male; F, female; HCC, Hürthle cells carcinoma; FTC, follicular thyroid carcinoma; TNM, tumor, node, and metastases staging; WI, widely invasive; EI, extrathyroidal invasion; M, multifocal; A, angioinvasion; PD, poorly differentiated areas; 131I, number of 131I treatments; TT, total thyroidectomy; HT, hemithyroidectomy; TTC, total thyroidectomy with cervical dissection; TG, thyroglobulin; M1, distant metastases; n.t., not tested; NED, no evidence of disease; BED, biochemical evidence of disease; SED, structural evidence of disease; D; death due to disease; I, remission or biochemical disease; II, structural disease or death due to disease.
| Patient | Histopathology | Treatment | Follow-up | Clinical outcome | Molecular analysis | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | Gender | Age at diagnosis (years) | TNM | Pattern | WI/EI/M/A/PD | Surgery/131I | Years | Last TG (ng/mL) | Anti-TG | M1 | NED | BED | SED | D | Group | RAS (K/N/H) |
RAC1b overexpression |
| 1 | F | 68 | T2NxMx | HCC | (−/−/−/+/−) | TT/1 | 5 | <0.2 | 0 | — | ✓ | I | (—/—/—) | − | |||
| 2 | F | 45 | T3NxMx | HCC | (−/−/−/+/−) | HT/0 | 8 | 1.7 | n.t. | — | ✓ | I | (—/—/—) | − | |||
| 3 | F | 40 | T3NxMx | FTC | (−/−/−/+/−) | HT/0 | 7 | 1.9 | n.t. | — | ✓ | I | (—/Q61R/—) | − | |||
| 4 | M | 38 | T3NxMx | FTC | (−/−/−/−/−) | TT/1 | 13 | <0.2 | 0 | — | ✓ | I | (—/—/—) | − | |||
| 5 | F | 70 | T3NxMx | FTC | (−/−/−/+/−) | TT/2 | 12 | <0.2 | 0 | — | ✓ | I | (—/—/—) | − | |||
| 6 | F | 63 | T3NxMx | FTC | (−/−/−/+/−) | TT/1 | 7 | <0.2 | 0 | — | ✓ | I | (—/—/—) | − | |||
| 7 | F | 57 | T2NxMx | HCC | (−/−/−/−/−) | HT/0 | 16 | 8.7 | n.t. | — | ✓ | I | (—/—/—) | + | |||
| 8 | F | 59 | T2NxMx | FTC | (−/−/−/−/−) | TT/1 | 15 | <0.2 | 0 | — | ✓ | I | (—/—/—) | + | |||
| 9 | M | 38 | T2NxMx | FTC | (−/−/−/−/−) | TT/1 | 11 | <0.2 | 0 | — | ✓ | I | (—/—/—) | − | |||
| 10 | F | 39 | T3NxMx | FTC | (+/−/−/+/+) | TT/2 | 9 | <0.2 | 0 | — | ✓ | I | (—/—/—) | − | |||
| 11 | F | 34 | T2NxMx | HCC | (−/−/−/−/−) | HT/0 | 7 | 11.1 | n.t. | — | ✓ | I | (—/—/—) | − | |||
| 12 | F | 39 | T2NxMx | FTC | (−/−/−/−/−) | TT/2 | 7 | 2.7 | n.t. | — | ✓ | I | (—/—/—) | − | |||
| 13 | F | 81 | T3NxMx | HCC | (−/+/−/−/−) | TT/1 | 4 | <0.2 | 0 | — | ✓ | I | (—/—/n.t.) | − | |||
| 14 | M | 39 | T3NxMx | FTC | (−/−/−/−/−) | TT/1 | 7 | <0.2 | 0 | — | ✓ | I | (—/—/—) | − | |||
| 15 | F | 49 | TxNxMx | FTC | (−/−/−/+/−) | HT/0 | 23 | <0.2 | 0 | — | ✓ | I | n.t. | − | |||
| 16 | F | 65 | T2NxMx | FTC | (−/−/−/+/−) | HT/0 | 6 | <0.2 | 0 | — | ✓ | I | (—/—/—) | − | |||
| 17 | F | 71 | T1NxM1 | HCC | (+/+/+/+/−) | TT/2 | 4 | 300000 | 0 | Lung adrenal gland | ✓ | II | n.t. | − | |||
| 18 | F | 42 | T3NxMx | HCC | (−/−/−/+/+) | TT/6 | 10 | 2108 | 0 | Lung | ✓ | II | (—/—/—) | + | |||
| 19 | M | 58 | T3NxM1 | FTC | (−/−/−/+/−) | TT/4 | 0 | 376 | 0 | Bone | ✓ | II | (—/Q61R/—) | + | |||
| 20 | M | 53 | T2NxMx | HCC | (+/−/+/+/−) | TT/4 | 7 | 632 | 0 | Lung | ✓ | II | (—/—/—) | + | |||
| 21 | M | 69 | T2NxM1 | FTC | (−/−/−/+/−) | TT/5 | 2 | 4668 | 0 | Bone, inguinal node | ✓ | II | (—/—/—) | + | |||
| 22 | M | 64 | T4aN1bMx | FTC | (+/+/−/+/+) | TTC/3 | 2 | 28.6 | 0 | Lung | ✓ | II | (—/—/—) | + | |||
| 23 | F | 87 | T3NxMx | FTC | (+/+/−/+/−) | TT/5 | 10 | 43500 | n.t. | Soft tissues | ✓ | II | (—/Q61L/—) | − | |||